Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Haemophilus influenzae b vaccine

A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib). Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine. These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	Haemophilus b conjugate vaccine Haemophilus b oligosaccharide conjugate vacccine Haemophilus influenzae B Polysaccharide Conjugate Vaccine (PRP-OMP) Haemophilus influenzae B Polysaccharide Conjugate Vaccine (PRP-T) Hib TITER vaccine
US brand name:	ActHIB HibTITER PedvaxHIB
NSC code:	722399

Haemophilus influenzae b vaccine

Search NCI's Drug Dictionary